Engineering Protein Expression RNA 
Broad Institute
JUNE 27, 2024
By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
MAY 22, 2024
What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?
The Pharma Data
DECEMBER 8, 2020
The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Laying down a new track for RNA processing, Remix launched with $81 million in financing.
Codon
APRIL 9, 2023
LanzaTech announced a partnership with H&M Move to convert factory carbon emissions into fabrics using engineered microbes. Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. RNA may offer a safer form of pest control in the future. Shrock E.L.
The Pharma Data
AUGUST 16, 2021
The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.
The Pharma Data
JANUARY 10, 2021
ILP100 is a genetically engineered Lactobacillus that acts as a small bioreactor on site in the wound, continuously introducing a chemokine, CXCL12, into the wound tissue. The drug is an RNA interference (RNAi) therapeutic. The study hit the mark on its primary biological endpoint of micro-dystrophin protein expression.
Expert insights. Personalized for you.
142 
Let's personalize your content